Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 41,719Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 10Letairis

PharmaCompass

01

Brand Name : Letairis

Ambrisentan

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Letairis

arrow
Fi Europe 2024
Not Confirmed

Ambrisentan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 314

2019 Revenue in Millions : 618

Growth (%) : -49

blank

02

Brand Name : Letairis

Ambrisentan

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Letairis

arrow
Fi Europe 2024
Not Confirmed

Ambrisentan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 206

2020 Revenue in Millions : 314

Growth (%) : -34

blank

03

Brand Name : Letairis

Ambrisentan

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Letairis

arrow
Fi Europe 2024
Not Confirmed

Ambrisentan

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 196

2021 Revenue in Millions : 206

Growth (%) : -5

blank

04

Brand Name : Letairis

Ambrisentan

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Letairis

arrow
Fi Europe 2024
Not Confirmed

Ambrisentan

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 142

2022 Revenue in Millions : 196

Growth (%) : -28

blank

05

Brand Name : Letairis

Ambrisentan

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Letairis

arrow
Fi Europe 2024
Not Confirmed

Ambrisentan

Main Therapeutic Indication : Antihypertensives

Currency : USD

2015 Revenue in Millions : 595

2014 Revenue in Millions : 700

Growth (%) : 18%

blank

06

Brand Name : Letairis

Ambrisentan

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Letairis

arrow
Fi Europe 2024
Not Confirmed

Ambrisentan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2016 Revenue in Millions : 819

2015 Revenue in Millions : 700

Growth (%) : 17

blank

07

Brand Name : Letairis

Ambrisentan

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Letairis

arrow
Fi Europe 2024
Not Confirmed

Ambrisentan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2017 Revenue in Millions : 887

2016 Revenue in Millions : 819

Growth (%) : 8

blank

08

Brand Name : Letairis

Ambrisentan

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Letairis

arrow
Fi Europe 2024
Not Confirmed

Ambrisentan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2018 Revenue in Millions : 943

2017 Revenue in Millions : 887

Growth (%) : 6%

blank

09

Brand Name : Letairis

Ambrisentan

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Letairis

arrow
Fi Europe 2024
Not Confirmed

Ambrisentan

Main Therapeutic Indication : Antihypertensives

Currency : USD

2014 Revenue in Millions : 14.40%

2013 Revenue in Millions :

Growth (%) :

blank

10

Brand Name : Letairis

Ambrisentan

arrow
Fi Europe 2024
Not Confirmed

Brand Name : Letairis

arrow
Fi Europe 2024
Not Confirmed

Ambrisentan

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2019 Revenue in Millions : 618

2018 Revenue in Millions : 943

Growth (%) : -34

blank